Redefining Human Ability

September 2015
FORWARD LOOKING STATEMENTS

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above.

Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Company Founded</td>
</tr>
<tr>
<td>2007</td>
<td>Exohiker™ debuted with 1000x less power consumption</td>
</tr>
<tr>
<td>2009</td>
<td>HULC™ licensed to Lockheed Martin</td>
</tr>
<tr>
<td>2010</td>
<td>Ekso™ prototype, an intelligent bionic exoskeleton, debuts</td>
</tr>
<tr>
<td>2011</td>
<td>Ekso Bionics™ begins testing at 10 leading centers worldwide</td>
</tr>
<tr>
<td>2012</td>
<td>Ekso™ first commercial exoskeleton delivered</td>
</tr>
<tr>
<td>2013</td>
<td>Able-bodied agreement with Lockheed Martin</td>
</tr>
<tr>
<td>2014</td>
<td>Variable-Assist introduced</td>
</tr>
<tr>
<td>2015</td>
<td>~1 million steps taken by Ekso exoskeletons</td>
</tr>
<tr>
<td></td>
<td>EKSO goes public</td>
</tr>
<tr>
<td></td>
<td>~15 million steps taken by Ekso exoskeletons</td>
</tr>
<tr>
<td></td>
<td>Ekso-Works unveiled</td>
</tr>
<tr>
<td></td>
<td>~32 million steps taken by our Ekso exoskeletons</td>
</tr>
<tr>
<td></td>
<td>Awarded third project with SOCOM</td>
</tr>
<tr>
<td></td>
<td>SmartAssist introduced in Europe</td>
</tr>
</tbody>
</table>
250+ man-years of exoskeleton knowledge
32M+ steps taken
$6.9 M LTM revenue

Patents:
- U.S. – 45 applications, of which 12 Issued
- Int’l – 116, of which 49 Issued

Business Verticals

**Military**
- "Iron Man"
  - Special Forces
  - Ground Soldiers
  - Maintenance/Logistics

**Medical**
- Ekso GT
  - Medical Device
  - Rehabilitation
  - Home/Wellness

**Industrial**
- Ekso Works
  - Construction
  - First Responders
  - Manufacturing
The Ekso GT with Variable Assist provides an innovative approach towards gait training for individuals affected by moderate to severe stroke.”

Arun Jayaraman PT, PhD

Ekso GT Medical Exoskeleton

Today’s Cutting Edge,
Tomorrow’s Standard of Care
ADJUSTMENTS:
LESS THAN 10 MINUTES

- Hip abduction/adduction angle
- Adjustable hip width
- Adjustable thigh length
- Hip & knee angles
- Ankle dorsiflexion stiffness
- Ankle resting position

SOFTWARE:
TUNE WHILE WALKING
- Tune spatial targets
- Tune Variable Assist settings
- Tune step length, height
- Adjust hip and knee flexion settings
- Adjust swing time

REAL TIME DATA CAPTURE:
SESSION SOFTWARE MONITORING
<table>
<thead>
<tr>
<th></th>
<th>Inpatient</th>
<th>Outpatient</th>
<th>Home</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCI</td>
<td>☑️ $</td>
<td>☑️ $</td>
<td>☐ $$$</td>
</tr>
<tr>
<td>Stroke</td>
<td>☑️ $$</td>
<td>☑️ $$</td>
<td>☐ $$$</td>
</tr>
<tr>
<td>Brain Injury</td>
<td>☑️ $$</td>
<td>☑️ $$</td>
<td>☐ $</td>
</tr>
<tr>
<td>Orthopedics</td>
<td>☐ $$$</td>
<td>☐ $$$</td>
<td>☐ $$</td>
</tr>
<tr>
<td>COPD, Heart Disease, Obesity</td>
<td>☐ $$$</td>
<td>☐ $$$</td>
<td>☐ $$$</td>
</tr>
<tr>
<td>MS, GB, Other Neurological Disorders</td>
<td>☑️ $$</td>
<td>☐ $</td>
<td></td>
</tr>
</tbody>
</table>

**Incidences per year (worldwide)**

<table>
<thead>
<tr>
<th></th>
<th>Percentage who could benefit rehabilitating with Ekso</th>
</tr>
</thead>
<tbody>
<tr>
<td>~16 million strokes(^{(1)})</td>
<td>~25%</td>
</tr>
<tr>
<td>~250,000-500,000 spinal cord injuries(^{(2)})</td>
<td>~75%</td>
</tr>
</tbody>
</table>

**Key:**

$ = ~$100-300M  
$$ = ~$500-800M  
$$$ = ~$1-3B
SMARTASSIST(3): NEXT GENERATION SOFTWARE

- For every stage of recovery.
- Stays with patients as they progress.

quick-fit | Stand/Sit | PreGait | SmartAssist | FreeGait | beyond
---|---|---|---|---|---
Remembers patient settings by number | Auto lean & Manual lean, Normal lean & Minimal lean | Squats, Marching, and Weight shift | More intuitive trajectory control | Stance variable assist | Gravity-supported walking | FES interface
Demonstrating success at leading centers

- Adoption strategy has been to target and penetrate world renowned rehab centers across the N. America and Europe

- "Gait training with the Ekso GT™ supports the re-learning of a correct step pattern and allows more steps at a faster speed than with traditional rehabilitation"
  Karen Nolan, PhD, Research Scientist
  Kessler Foundation

- Success to date:
  - ~32.8 Million Steps (8 Sept)
  - ~145 Units Sold or Rented (thru Q2 ‘15)
  - ~100 Customers (thru Q2 ‘15)
  - ~23 Countries (thru Q2 ‘15)
  - ~16 Multi Unit Centers (thru Q2 ‘15)
HOW EKSO PAYS FOR ITSELF TODAY

PATIENT RECRUITMENT:
• Facilities with Ekso attract more Stroke and SCI inpatients
• Increase of patient catchment area

EARLY MOBILIZATION:
• Ekso mobilizes patients earlier than would otherwise be economically and otherwise be feasible
• Existing data on early mobilization suggests this should result in earlier discharges.

WORKERS COMPENSATION:
• Ekso keeps patients from collapsing at the knees or hips.
• We believe this will result in less physical therapist back injuries in the rehab.

Good Shepherd Rehabilitation

✓ Within 3 months, 35+ hours of usage per week
✓ Staff saw better outcomes and quicker improvements
✓ Transitioned from 2 PT’s to 1 PT’s
✓ Expanded patient catchment area to 6-hours
✓ 37% contribution margin
✓ 50% of outpatients did not require gait training if used Ekso during inpatient
Weight bearing activities including standing and walking have been proven to mitigate common secondary complications and have psychological benefits for people with chronic SCI.

Early mobilization post-stroke has been demonstrated to improve outcomes for some stroke victims.

Studies have shown that stroke patients require rehabilitation involving repetitive and intense practice that is task specific.

- These factors contribute to improved neuroplasticity (*the mechanism by which the damaged brain relearns lost behavior in response to rehabilitation*) and
- motor function.
Relevant outcomes across eight case series included:

- **Reduction in spasticity and pain** were reported for SCI patients (5).

- Clinically meaningful improvements in mobility, walking speed and distance were reported in both incomplete and complete SCI patients (6)(7).

- Statistically significant and clinically meaningful improvements in gait parameters were reported for chronic stroke patients (8).

- Minimally ambulatory stroke inpatients (FIM score <30 at admission) showed larger functional gains with robotic exoskeleton therapy compared to individuals receiving traditional gait training (9).

- Improvements in bladder function, strength and endurance in treated SCI patients were reported (10).

- SCI patients reported positive psychological effects on wellbeing and motivation (11)(12).

- Across the studies, Ekso use was demonstrated to be safe and feasible for use in both stroke and SCI patients (13)(14)(15)(16).
Ekso Labs

“SOCOM’s Iron Man Suit Sees Astounding Progress”

Admiral William H. McCraven
Ninth Commander
U.S. Special Operations Command
- Pro-actively **develop** exoskeleton **technology**
  - Seek/develop programs to solve next critical exoskeleton challenges
  - Serve as a second R&D arm for Ekso Bionics
- **Collaborate** with **world-class** agencies, universities and companies
- Enable consistent **growth in** IP portfolio
- **License technology** to industry partners where complementary
- **Cash flow generative**
  - Earn gross profit from services work
  - Earn royalties and license fee over time
BROAD IP PORTFOLIO AND GROWING

**Patent Summary**

**45 U.S. Patents**
- 12 issued
- 23 in prosecution
- 10 provisional

**116 Int’l Patents**
- 67 in prosecution
- 49 issued

- Methods on how medical exoskeleton decides when to start walking
- Basic exoskeleton IP Variable Assist
- Add-ons that will not apply until medical device is in the field

**Medical**
- Light weight
- Proven Technology
- Strength augmentation
- Natural range of motion
- Load carriage (load bearing)
- Ultra Low Power Consumption
- Novel Actuation strategies
- Exoskeleton geometries for tool holding & load lifting
- Enhanced endurance
- Proven technology
- Safe and effective
- Energy efficiency

**Commercial / Industrial**
- Energy efficient load carriage
- Un-actuated exoskeleton structure
- Control methods for assisting walking
- Efficient hydraulic actuation

**Military**

Copyright © 2015 Ekso Bionics, Inc. All rights reserved.
Industrial Exoskeletons
A passive, light-weight, intuitive tool that can:
- Enable unparalleled levels of **productivity**
- Change the way the job gets done
- Enhance user **safety** and job satisfaction
- Improve **workmanship**
- Expand **workforce/pool**
Unstructured environment
- Where a wheeled or robotic solution won’t work

Dynamic environment
- Where the worker is moving around; fixed solutions won’t work

Heavy load
- One that hurts productivity by necessitating frequent pauses in the work

High Frequency and Long Duration Lifting

Initial Successes with:
- Overhead drilling, Welding, Grinding, Diamond cutting
- Construction and tool companies; potential channel partners
Financial Overview
### FINANCIAL SUMMARY

**Revenues**

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
<th>H1 2015</th>
<th>H1 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td>$2,924</td>
<td>$1,612</td>
<td>$2,033</td>
<td>$1,217</td>
</tr>
<tr>
<td>Engineering Services</td>
<td>2,403</td>
<td>1,690</td>
<td>1,770</td>
<td>1,042</td>
</tr>
<tr>
<td><strong>Total Revenues</strong></td>
<td><strong>5,327</strong></td>
<td><strong>3,302</strong></td>
<td><strong>3,803</strong></td>
<td><strong>2,259</strong></td>
</tr>
</tbody>
</table>

**Gross Profit**

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
<th>H1 2015</th>
<th>H1 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td>876</td>
<td>151</td>
<td>265</td>
<td>385</td>
</tr>
<tr>
<td>Engineering Services</td>
<td>683</td>
<td>436</td>
<td>640</td>
<td>140</td>
</tr>
<tr>
<td><strong>Total Gross Profit</strong></td>
<td><strong>1,559</strong></td>
<td><strong>587</strong></td>
<td><strong>905</strong></td>
<td><strong>525</strong></td>
</tr>
</tbody>
</table>

**Operating Expenses**

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
<th>H1 2015</th>
<th>H1 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales and Marketing</td>
<td>7,085</td>
<td>4,291</td>
<td>4,374</td>
<td>3,380</td>
</tr>
<tr>
<td>Research and Development</td>
<td>3,868</td>
<td>2,677</td>
<td>2,725</td>
<td>1,468</td>
</tr>
<tr>
<td>General and Administrative</td>
<td>7,400</td>
<td>3,913</td>
<td>3,534</td>
<td>3,880</td>
</tr>
<tr>
<td><strong>Total Operating Expenses</strong></td>
<td><strong>18,353</strong></td>
<td><strong>10,881</strong></td>
<td><strong>10,633</strong></td>
<td><strong>8,728</strong></td>
</tr>
</tbody>
</table>

**Operating Inc(Loss)**

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
<th>H1 2015</th>
<th>H1 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>(16,794)</td>
<td>(10,294)</td>
<td>(9,728)</td>
<td>(8,203)</td>
<td></td>
</tr>
</tbody>
</table>

**Net Loss**

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
<th>H1 2015</th>
<th>H1 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ (33,769)</td>
<td>$ (11,887)</td>
<td></td>
<td>$ (9,760)</td>
<td>$ (25,638)</td>
</tr>
</tbody>
</table>

**Loss per share**

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
<th>H1 2014</th>
<th>H1 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ (0.43)</td>
<td>$ (0.57)</td>
<td></td>
<td>$ (0.10)</td>
<td>$ (0.35)</td>
</tr>
</tbody>
</table>

**Cash on Hand**

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
<th>H1 2014</th>
<th>H1 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ 25,190</td>
<td>$ 805</td>
<td></td>
<td>$ 16,251</td>
<td>$ 10,965</td>
</tr>
</tbody>
</table>
“The incorporation of exoskeleton technology into the therapy program has enhanced our capabilities to provide rehabilitation care to our Active Duty and Veteran personnel”
Doug Ota, M.D., Chief SCI Service VA
Palo Alto Health Care System

“We can give them the protection they need, the mobility they need, the situational awareness they need, in order to complete the mission”
Admiral William McRaven, SOCOM

“I would never try a task like overhead grinding again without a system like this”
Charles W. Osborne, PSNS & IMF employee
3) This generation of Variable Assist software is currently only available outside the US.
4) Eight case series studies included N=53 total subjects (N=13 stroke, N=36 chronic complete SCI, N=4 chronic incomplete SCI). Training programs reported ranged from 6 sessions for 1 wk to 3x/wk for 4 wks with 1 study reporting use of 3x/wk for 1 yr.
8) Angacian G et al., Quantifying Gait Outcomes in Chronic Stroke using Two Robotic Training Protocols, Burke Summer Student Presentation
9) Oh-Park M et al., Benefits of inpatient rehabilitation post stroke, AAP Poster 2015
10) Roth T et al., If the Paralyzed Walk Again: Experiences with the exoskeleton Ekso Bionics, DMPG Poster 2014.
12) Roth T et al., If the Paralyzed Walk Again: Experiences with the exoskeleton Ekso Bionics, DMPG Poster 2014.
15) Oh-Park M et al., Benefits of inpatient rehabilitation post stroke, AAP Poster 2015
16) These statements have not been evaluated by the FDA and the Ekso GT has not received 510(k) clearance. The Company has filed a 510(k) notification which is currently under review by the FDA.